Memantin v terapii dementsii


Cite item

Full Text

About the authors

M. A Anikina

ГБОУ ДПО РМАПО, Москва

Кафедра неврологии ГБОУ ДПО РМАПО

E. E Vasenina

ГБОУ ДПО РМАПО, Москва

Кафедра неврологии ГБОУ ДПО РМАПО

O. S Levin

ГБОУ ДПО РМАПО, Москва

Кафедра неврологии ГБОУ ДПО РМАПО

References

  1. Гаврилова С.И. Фармакотерапия болезни Альцгеймера. М., 2003.
  2. Дамулин И.В. Сосудистая деменция и болезнь Альцгеймера. М., 2002.
  3. Левин О.С. Алгоритмы диагностики и лечения деменции. М., 2012.
  4. Левин О.С. Деменция с тельцами Леви. М., 2006.
  5. Одинак М.М., Литвиненко И.В., Емелин А.Ю. Открытое сравнительное исследование эффективности мемантина в терапии посттравматических когнитивных расстройств. Неврологич. журн. 2005; 6: 32–7.
  6. Яхно Н.Н. Актуальные вопросы нейрогериатрии. В кн.: Достижения в нейрогериатрии. М., 1995; с. 9–27.
  7. Aupperle P.M., Tariot P.N., Safirstein B. et al. Long - term safety and efficacy of memantine treatment in moderate to severe Alzheimer’s disease. Eur J Neurology 2007; 14 (1): 1097.
  8. Cummings J.L., Frank J.C., Cherry D. et al. Guidelines for managing Alzheimer’s disease. Am Fam Physician 2002; 65: 2525–34.
  9. Cummings J.L. Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer’s disease. Neurology 2005; 65 (3): 18–24.
  10. Cummings J.L., Schneider E, Tariot P. et al. Behavioral effects of memantine in Alzheimer’s disease patients receiving donepezil treatment. Neurology 2006; 67: 57–63.
  11. Cummings J.L., Grossberg G, Green P. et al. Review of the safety and tolerability of treatment for moderate to severe AD. Eur J Neurology 2007; 14 (1): 1090.
  12. Doody R.S., Stevens J.C., Beck R.N. et al. Practice parameter: management of dementia (an evidence - based review). Neurology 2001; 56: 1154–66.
  13. Doody R.S., Wirth Y, Schmitt F. et al. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer’s disease. Dement Geritr Cogn Disord 2004; 18: 227–32.
  14. Farlow M.R., Cummings J.L. Effective Pharmacologic Management of Alzheimer’s disease. Am J Med 2007; 120: 388–97.
  15. Francis P.T. Behavioral effects of memantine: understanding the pharmacological rationale. Eur J Neurology 2007; 14 (1): 2098.
  16. Gauthier S, Wirth Y, Mobius H.J. Effects of memantine on behavioral symptoms in Alzheimer disease patients. Int J Geriatr Psychiatry 2005; 20: 459–64.
  17. Gauthier S (ed.). Clinical diagnosis and management of Alzheimer’s disease. London. Inf Health Care 2007.
  18. Graham S, Resnick E.M., Tocco M. et al. Memantine is safe and effective in the treatment of moderate to severe Alzheimer’s disease: updated meta - analysis. Eur J Neurology 2007; 14 (1): 1096.
  19. Li L, Sengupta A, Haque N et al. Memantine inhibits and reverses the Alzheimer’s type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Letters 2004; 566: 261–9.
  20. Lyketos C.G., Colenda C.C., Beck C. et al. Position statement of AAGP regarding principles of care for patients with dementia resulting from Alzheimer's disease. Am J Geriatr Psychiatry 2006; 14: 561–73.
  21. Mendez M.F., Cummings J. Dementia. Philadelphia, Butterworth Heinemann 2003.
  22. Orgogozo J.M., Rigaud A.S., Stöffler A. et al. Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300). Stroke 2002; 33: 1834–9.
  23. Parsons C.G., Danysz W, Quack G. Memantine is clinically well tolerated NMDA-receptor antagonist. Neuropharmacology 1999; 38: 735–67.
  24. Petersen K.A. Compliance and practical considerations in the management of Alzheimer’s disease with memantine. Eur J Neurology 2007; 14 (1): 1107.
  25. Peskind E.R., Potkin S.G., Pomara N. et al. Memantine treatment in mild to moderate Alzheimer’s disease. Am J Geriatr Psychiatry 2006; 14: 704–15.
  26. Reisberg B, Doody R, Stoffler A, Schmitt F et al. Memantine in moderate - to - severe Alzheimer’s disease. N Engl J Med 2003; 348: 1333–41.
  27. Reisberg B, Doody R, Stoffler A et al. A 24-week open - label extension study of memantine in moderate to severe Alzheimer’s disease. Arch Neurol 2006; 63: 49–54.
  28. Rogawski M.A., Wenk G.L. The neuropharmacological basis for the use of mementine in the treatment of Alzheimer’s disease. CNS Drug Rev 2003; 9: 275–308.
  29. Scharre D.W. Galantamine with adjunctive memantine: combined effects on brain nicotinic acetylcholine receptors and NMDA receptors may improve Alzheimer’s disease symptomatology. J Clin Pharmacol 2006; 46: 6.
  30. Schmidt R, Ropele S, Ebenbauer B. et al. Memantine effects on brain volume, glucose metabolism and cognition in AD patients. Eur J Neurology 2007; 14 (1): 2526.
  31. Sonkusare S.K., Kaul C.L., Ramarao P. Dementia of Alzheimer’s disease and other neurodegenerative disorders – memantine, a new hope. Pharmacol Research 2005; 51: 1–17.
  32. Stoffler A, Wirth Y, Mobius H.J. Treatment of vascular dementia with memantine over one year. Eur J Neurology 2005; 12 (1): 2089.
  33. Tariot P.T., Farlow M.R., Grossberg G.R. et al. Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial JAMA 2004; 291: 317–24.
  34. Tocco M, Resnick E.M., Graham S. et al. Cognitive effects of memantine in moderate to severe Alzheimer’s disease: a responder analysis. Eur J Neurology 2007; 14 (1): 1098.
  35. Waldemar G, Dubois B, Emre M. et al. Alzheimer’s disease and other disorders associated with dementia. R.Hughes et al. European handbook of neurological management. Oxford. Blackwell Publishing 2006; p. 266–98.
  36. Wilkinson D, Andersen H.F. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord 2007; 24: 138–45.
  37. Wilcock G, Möbius H.J., Stöffler A. A double - blind, placebo - controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol 2002; 17: 297–305.
  38. Winblad B, Jones R, Wirth Y. et al. Memantine in moderate to severe Alzheimer’s disease: meta - analysis of randomized clinical trials. Dement Geriatr Cogn Disord 2007; 24: 20–7.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies